Targets › POLR1A
2 programs from 2 companies in 5 trials: 5 Phase 1; Oncology; next expected readout Dec 2026.
Catalytic core component of RNA polymerase I (Pol I), a DNA-dependent RNA polymerase which synthesizes ribosomal RNA precursors using the four ribonucleoside triphosphates as substrates. Transcribes 47S pre-rRNAs from multicopy rRNA gene clusters, giving rise to 5.8S, 18S and 28S ribosomal RNAs. (UniProt, O95602)
Open in Phaseline: the race on POLR1A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Pidnarulex RNA Polymerase I inhibitor | POLR2A, POLR1A | Phase 1 | Metastatic Malignant Solid Neoplasm; Metastatic Colorectal Adenocarcinoma; Anatomic Stage III Breast Cancer AJCC v8; Burkitt Lymphoma | Dec 2026 |
| Senhwa Biosciences | CX-5461 POLR2A/POLR1A inhibitor; transcription inhibitor targeting ribosomal RNA synthesis | POLR2A, POLR1A | Phase 1 | Advanced Solid Tumor | Mar 2027 |
Metastatic Malignant Solid Neoplasm (1) Metastatic Colorectal Adenocarcinoma (1) Anatomic Stage III Breast Cancer AJCC v8 (1) Burkitt Lymphoma (1) Advanced Solid Tumor (1)
mixed (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.